title: Stimulation of tear secretion by topical agents that increase cyclic nucleotide levels.
abstract: The authors examined the effect of topical application of agents known to increase cyclic nucleotide levels on tear secretion by accessory lacrimal gland tissue in their rabbit model for keratoconjunctivitis sicca (KCS). Tear secretion was studied by changes in tear film osmolarity and tear volume caused by application of the agents relative to application of isotonic buffer solution alone. A decrease in tear film osmolarity or increase in tear volume was interpreted as an increase in tear secretion. Irritative stimulation was distinguished from pharmacologic stimulation by the prior use of topical proparacaine. The following agents significantly decreased tear film osmolarity and increased tear volume: vasoactive intestinal peptide (2 X 10(-8) to 2 X 10(-6) M); three pro-opiomelanocortin fragments alpha-, beta-, and gamma-melanocyte stimulating hormone at 10(-4), 10(-3), and 10(-3) M, respectively; the permeable cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) analogs 8-Br cAMP (0.3-3.0 X 10(-3) M) and 8-Br cGMP (1.0-10.0 X 10(-3) M); and the cyclic nucleotide phosphodiesterase inhibitor 1-isobutyl-3-methyl xanthine (0.3-3.0 X 10(-3) M). Forskolin (2 X 10(-4) M), which activates the catalytic subunits of adenyl cyclase, increased tear volume significantly. Secretin, adrenocorticotropic hormone, and pilocarpine were ineffective. The authors conclude that agents that increase either cAMP or cGMP levels pharmacologically stimulated tear secretion when applied topically to rabbit eyes with surgically induced KCS.
authors.affiliation: Eye Research Institute, Boston, Massachusetts 02114.
authors.forename: J P
authors.initials: JP
authors.lastname: Gilbard
authors.forename: S R
authors.initials: SR
authors.lastname: Rossi
authors.forename: K G
authors.initials: KG
authors.lastname: Heyda
authors.forename: D A
authors.initials: DA
authors.lastname: Dartt
mesh_terms: D000287:Administration, Topical; D000818:Animals; D005576:Colforsin / Q000494:pharmacology; D004195:Disease Models, Animal; D005260:Female; D007637:Keratoconjunctivitis / Q000378:metabolism*; D007638:Keratoconjunctivitis Sicca / Q000378:metabolism*; D007765:Lacrimal Apparatus / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D009712:Nucleotides, Cyclic / Q000096:biosynthesis*; D009883:Ophthalmic Solutions / Q000008:administration & dosage / Q000494:pharmacology*; D009994:Osmolar Concentration; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D010862:Pilocarpine / Q000494:pharmacology; D011333:Pro-Opiomelanocortin / Q000494:pharmacology; D011817:Rabbits; D015398:Signal Transduction / Q000187:drug effects; D013666:Tears / Q000378:metabolism*; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology
chemical_list: D009712:Nucleotides, Cyclic; D009883:Ophthalmic Solutions; D010726:Phosphodiesterase Inhibitors; D010862:Pilocarpine; D005576:Colforsin; D014660:Vasoactive Intestinal Peptide; D011333:Pro-Opiomelanocortin